Browse our comprehensive archive of press releases by date.
Select a specific day to access all press releases published on Middle East News Digest.
Press releases published on April 28, 2025
Duke Robotics Evaluating Drone Operators in Preparation for Commencement of Activities in Greece
GlobeNewswire
·
April 28, 2025
FT. LAUDERDALE, FL, April 28, 2025 (GLOBE NEWSWIRE) -- Duke Robotics Corp. (OTCQB) ("Duke Robotics" or the "Company"), a leader in advanced robotics technology and autonomous drone solutions, today announced significant progress in its efforts to identify …
Purple Biotech Reports Positive NT219 Data at AACR for Colorectal and Head and Neck Cancers
GlobeNewswire
·
April 28, 2025
Activated b-catenin or loss of its negative regulator adenomatous polyposis coli (APC) is a potential biomarker for NT219 in the treatment of colorectal cancer NT219’s mechanism of action informs how it can restore efficacy of immunotherapies and expand …
Trust Wallet Launches ‘Stablecoin Earn’ to Boost Crypto Earning Opportunities*
GlobeNewswire
·
April 28, 2025
Users can earn seamlessly on stablecoins with flexible, secure onchain strategies — while maintaining full control over assets. DUBAI, United Arab Emirates, April 28, 2025 (GLOBE NEWSWIRE) -- Trust Wallet, the world’s leading self-custody Web3 wallet …
ImPact Biotech Presents Updated Efficacy Data from Evaluation of Padeliporfin VTP in LG UTUC and Intermediate-Risk Prostate Cancer at AUA 2025
GlobeNewswire
·
April 28, 2025
– Complete response (CR) observed in 79% (26/33) of evaluable patients with low-grade upper tract urothelial cancer (UTUC) who completed the Induction Treatment Phase (ITP) of the ENLIGHTED Phase 3 trial evaluating Padeliporfin VTP in UTUC – – Padeliporfin …
MediWound to Present New EscharEx® Data at Leading Wound Care Conferences
GlobeNewswire
·
April 28, 2025
Presentations at WHS and SAWC to highlight EscharEx’s mechanism of action, preclinical advantages over SANTYL®, and new data in treating VLUs and DFUs Findings reinforce the ongoing Phase III study in VLUs and support the planned DFU trial strategy YAVNE, …
Quanta Therapeutics Presents Late-Breaking Data for QTX3544, an Oral G12V-Preferring Multi-KRAS Inhibitor, at AACR Annual Meeting 2025
GlobeNewswire
·
April 28, 2025
- Preclinical data demonstrates synergy of QTX3544 with EGFR inhibitors, broadly enhancing anti-tumor activity - - Data supports ongoing Phase 1 clinical trial for QTX3544 as monotherapy and in combination with cetuximab in patients with KRASG12V mutations …
LayerX Security Extends Series A Funding to $37M to Power Next-Gen Enterprise Browser Security, Challenges SSE Solutions and Enterprise Browsers
GlobeNewswire
·
April 28, 2025
NEW YORK, April 28, 2025 (GLOBE NEWSWIRE) -- LayerX, the leading Secure Enterprise Browser Extension, today announced it has raised an $11 million extension to its $26 million Series A funding round, bringing the total amount raised to $45 million. The …
Pluri Completes Strategic Acquisition of Leading Cultivated Cacao AgFoodTech Company, Kokomodo Ltd.
GlobeNewswire
·
April 28, 2025
Acquisition of approximately 71% stake in Kokomodo Ltd. Acquisition uniquely combines Pluri's mass-scale cell production expertise with Kokomodo Ltd.’s ability to craft real, controlled, climate-resilient cacao using cellular agriculture technology HAIFA, …
Silo Pharma Expands Intellectual Property Portfolio with Patent Application for Exclusively Licensed Alzheimer’s Drug
GlobeNewswire
·
April 28, 2025
SARASOTA, FL, April 28, 2025 (GLOBE NEWSWIRE) -- Silo Pharma, Inc. (Nasdaq: SILO) (“Silo” or the “Company”), a developmental stage biopharmaceutical company focused on novel therapeutics and drug delivery systems, today announced the filing of a patent …
Gilat to Participate in the 20th Annual Needham Technology, Media & Consumer Conference on May 13th, 2025
GlobeNewswire
·
April 28, 2025
PETAH TIKVA, Israel, April 28, 2025 (GLOBE NEWSWIRE) -- Gilat Satellite Networks Ltd. (NASDAQ, TASE: GILT), a worldwide leader in satellite networking technology, solutions, and services, today announced management’s participation in the 20th Annual …
BPGbio CEO Dr. Niven R. Narain Named to The Medicine Maker Power List 2025
GlobeNewswire
·
April 28, 2025
BOSTON, April 28, 2025 (GLOBE NEWSWIRE) -- BPGbio, Inc., a biology-first, AI-powered clinical-stage biopharma company, today announced that President and CEO Niven R. Narain, Ph.D. has been named to The Medicine Maker’s Power List 2025. The annual list …
Hudbay’s Eugene Lei wins Globe and Mail’s Report on Business 2025 Best Executive Award
GlobeNewswire
·
April 28, 2025
TORONTO, April 28, 2025 (GLOBE NEWSWIRE) -- Hudbay Minerals Inc. (“Hudbay” or the “Company”) (TSX, NYSE: HBM) is pleased to announce that Eugene Lei, Chief Financial Officer at Hudbay, has been recognized as a winner of the Globe and Mail’s Report on …
Neumora Therapeutics to Report First Quarter 2025 Financial Results on Monday, May 12, 2025
GlobeNewswire
·
April 28, 2025
WATERTOWN, Mass., April 28, 2025 (GLOBE NEWSWIRE) -- Neumora Therapeutics, Inc. (Nasdaq: NMRA), a clinical-stage biopharmaceutical company with a therapeutics pipeline consisting of seven brain disease programs including two clinical-stage programs, today …
Arvinas to Report First Quarter 2025 Financial Results on Thursday, May 1, 2025
GlobeNewswire
·
April 28, 2025
NEW HAVEN, Conn., April 28, 2025 (GLOBE NEWSWIRE) -- Arvinas, Inc. (Nasdaq: ARVN), a clinical-stage biotechnology company working to develop a new class of drugs based on targeted protein degradation, today announced that management will review first …
Ampersand Biomedicines Presents Preclinical Data on AMP-410, a Novel Anti-VEGF/4-1BB Bifunctional AND-Body™ Therapeutic, at AACR 2025
GlobeNewswire
·
April 28, 2025
Lead development candidate, AMP-410, leverages proprietary Ampersand technology to block VEGF and allosterically activate 4-1BB signaling – unlike traditional bispecific molecules – driving both adaptive and innate anti-tumor activity In multiple …
Ocular Therapeutix™ to Report First Quarter 2025 Financial Results on May 5, 2025
GlobeNewswire
·
April 28, 2025
BEDFORD, Mass., April 28, 2025 (GLOBE NEWSWIRE) -- Ocular Therapeutix, Inc. (NASDAQ: OCUL, “Ocular”), a biopharmaceutical company committed to redefining the retina experience, today announced that it plans to issue a press release regarding first quarter …
Beamr to Participate in Upcoming Investor Conferences in May 2025
GlobeNewswire
·
April 28, 2025
Beamr will present at the Ladenburg Thalmann Technology Innovation Expo in New York, and participate virtually in the Needham 1x1 Conference Herzliya, Israel, April 28, 2025 (GLOBE NEWSWIRE) -- Beamr Imaging Ltd. (NASDAQ: BMR), a leader in video …
XORTX Announces Grant of European Patent
GlobeNewswire
·
April 28, 2025
CALGARY, Alberta, April 28, 2025 (GLOBE NEWSWIRE) -- XORTX Therapeutics Inc. ("XORTX" or the “Company”) (NASDAQ: XRTX | TSXV: XRTX | Frankfurt: ANU), a late stage clinical pharmaceutical company focused on developing innovative therapies to treat gout and …
Nayax to Showcase End-to-End Payment Ecosystem at The NAMA Show, May 7-9 in Las Vegas
GlobeNewswire
·
April 28, 2025
HERZLIYA, Israel, April 28, 2025 (GLOBE NEWSWIRE) -- Nayax Ltd. (Nasdaq: NYAX; TASE: NYAX), a global commerce enablement payments and loyalty platform designed to help merchants scale their business, will be showcasing its range of solutions at The NAMA …
Arvinas Shares New Preclinical Combination Data for the PROTAC BCL6 Degrader, ARV-393, at the 2025 American Association for Cancer Research Annual Meeting
GlobeNewswire
·
April 28, 2025
– ARV-393 demonstrated strong synergistic antitumor activity, including complete regressions, in combination with standard-of-care chemotherapy, biologics, and select investigational oral small molecule inhibitors – – Findings support continued evaluation …